Saturday 17 October 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
In the quarter to June 2026, EPS grew 38.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
1.55
0.04
−2.52%
Follow SKYE
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to October
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 600.00 | 200.00 | 100.00 | 210.00 | 50.00 | 78.00 | 22.00 | 11.52 | 18.00 | 5.47 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 3,600.00 | 1,000.00 | 1,200.00 | 2,340.00 | 400.00 | 518.00 | 134.00 | 112.00 | 155.28 | 46.00 | |||||
| People | |||||||||||||||
| People | Employees | 2 | 3 | 3 | 4 | 6 | 9 | 11 | 7 | 16 | 12 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) | |||||
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (340.00) | (205.54) | (320.00) | 15.56 | (60.00) | (40.00) | (80.00) | (42.96) | (5.84) | (11.28) | |||||
| Cash flow | (373.99) | (237.95) | (65.07) | (89.17) | (52.46) | (31.85) | (45.91) | (15.93) | (5.53) | (8.69) | |||||
| Capex | (1.17) | (1.41) | (0.07) | 0.00 | (0.06) | (0.45) | (0.10) | 6.30 | (0.05) | 0.07 | |||||
| Free cash flow | (375.16) | (239.36) | (65.14) | (89.17) | (52.52) | (32.30) | (46.01) | (9.63) | (5.59) | (8.61) | |||||
| Book value | (152.73) | (57.15) | (256.80) | 8.11 | 3.91 | 28.85 | (10.84) | (2.43) | 14.94 | 4.04 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (4) | (3) | (4) | (6) | (6) | (6) | (13) | (14) | (25) | (43) | ||||
| Capex | 0 | 0 | 0 | — | 0 | 0 | 0 | 6 | 0 | 0 | |||||
| Free cash flow | (4) | (3) | (4) | (6) | (6) | (7) | (13) | (8) | (25) | (43) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 0 | 0 | (14) | 1 | 2 | 6 | (3) | (2) | 66 | 19 | ||||
| Total debt | — | 0 | 1 | 0 | 1 | 2 | 2 | 4 | — | — | |||||
| Net debt | 0 | 0 | 0 | (1) | (2) | (7) | 1 | (6) | (68) | (26) | |||||
| Shareholders’ equity | (1) | (1) | (16) | 1 | 0 | 6 | (3) | (2) | 68 | 20 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (182.72) | (939.88) | (1,526.80) | 53.20 | (281.07) | (136.06) | (205.43) | (357.64) | (62.73) | (110.66) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | 184.06 | 127.65 | 200.65 | (14.01) | (1,313.58) | (269.90) | (1,364.21) | 1,464.81 | (80.48) | (126.85) | |||||
Negative figures in brackets.
Fiscal years to Oct 2013 · latest quarter Jul 2014
Charts ten years each
Skye Bioscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CALC CalciMedica Inc. | $7.4M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XCUR Exicure, Inc. | $7.3M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $7.0M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.0M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| NIKI Niki BioSolutions, Inc. | $6.9M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| AIM AIM ImmunoTech Inc. | $6.8M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.7M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $6.9M | — | — | −39.66% | — | +26.51% | 0.00% | 0.00% |
Skye Bioscience, Inc. (SKYE) key facts
- Skye Bioscience, Inc. (SKYE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SKYE traded at $1.55, a market capitalization of $7.0 million.
- Return on equity was −126.9% and debt-to-equity 0.00.